Ensiklopedia Dunia

Technopedia Center

Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education

Solabegron - Wikipedia

From Wikipedia, the free encyclopedia

Solabegron
Clinical data

Other names	3-[3-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethylamino]phenyl]benzoic acid
ATC code	None
Identifiers
IUPAC name 3'-[(2-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]-3-biphenylcarboxylic acid
CAS Number	252920-94-8^Y HCl: 451470-34-1^Y
PubChem CID	9887812
ChemSpider	8063484^N
UNII	55P6YH9O6N HCl: GU14FR8D4A^Y
KEGG	D05879^Y
ChEBI	CHEBI:141346
CompTox Dashboard (EPA)	DTXSID40963347
Chemical and physical data
Formula	C₂₃H₂₃ClN₂O₃
Molar mass	410.90 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1=CC(=CC(=C1)C(=O)O)C2=CC(=CC=C2)NCCNC[C@@H](C3=CC(=CC=C3)Cl)O
InChI InChI=1S/C23H23ClN2O3/c24-20-8-2-6-18(13-20)22(27)15-25-10-11-26-21-9-3-5-17(14-21)16-4-1-7-19(12-16)23(28)29/h1-9,12-14,22,25-27H,10-11,15H2,(H,28,29)/t22-/m0/s1^N Key:LLDXOPKUNJTIRF-QFIPXVFZSA-N^N
^NY (what is this?) (verify)

Solabegron (code name GW-427,353) is a drug which acts as a selective agonist for the β₃ adrenergic receptor. It is being developed for the treatment of overactive bladder and irritable bowel syndrome.^[1]^[2]^[3] It has been shown to produce visceral analgesia by releasing somatostatin from adipocytes.^[4]^[5]

Solabegron was discovered by GlaxoSmithKline and acquired by AltheRx in March 2011. Solabegron relaxes the bladder smooth muscle by stimulating β₃ adrenoceptors, a novel mechanism compared with older established drug treatments for overactive bladder syndrome such as the anticholinergic agents. Astellas Pharma has developed the first commercially available β₃ adrenergic receptor, mirabegron, which is now licensed in Japan^[6] and the U.S.^[7] exclusively for treatment of overactive bladder syndrome.

A Phase II study of solabegron for overactive bladder (OAB) looked at 258 patients with moderate-to-severe incontinence experiencing an average of 4.5 wet episodes per day. Results demonstrated a statistically significant improvement with solabegron as compared with placebo, as measured by the percentage reduction of the number of wet episodes and the absolute number of daily voids.

A Phase II study for irritable bowel syndrome (IBS) evaluated 102 patients with IBS. Solabegron demonstrated significant reduction in pain associated with the disorder and a trend for greater improvement in the quality of life, when compared with a placebo.

Both Phase II studies indicated a tolerability profile for solabegron that was similar to placebo. This drug does not bind to acetylcholine receptors so side effects are expected to be minor.

AltheRx is currently preparing to advance solabegron into a large clinical study in OAB.

References

^ Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C, et al. (October 2007). "GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog". The Journal of Pharmacology and Experimental Therapeutics. 323 (1): 202–9. doi:10.1124/jpet.107.125757. PMID 17626794. S2CID 19281697.
^ Grudell AB, Camilleri M, Jensen KL, Foxx-Orenstein AE, Burton DD, Ryks MD, et al. (May 2008). "Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health". American Journal of Physiology. Gastrointestinal and Liver Physiology. 294 (5): G1114-9. doi:10.1152/ajpgi.00051.2008. PMID 18372395.
^ Kelleher DL, Hicks KJ, Cox DS, et al. (2008). "Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS)". Neurogastroenterol Motil. 20 (Suppl 2): 131.
^ Cellek S, Thangiah R, Bassil AK, Campbell CA, Gray KM, Stretton JL, et al. (July 2007). "Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system". Gastroenterology. 133 (1): 175–83. doi:10.1053/j.gastro.2007.05.009. PMID 17631141.
^ Schemann M, Hafsi N, Michel K, Kober OI, Wollmann J, Li Q, et al. (January 2010). "The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin". Gastroenterology. 138 (1): 266–74. doi:10.1053/j.gastro.2009.09.046. PMID 19786030.
^ Gras J (January 2012). "Mirabegron for the treatment of overactive bladder". Drugs of Today. 48 (1): 25–32. doi:10.1358/dot.2012.48.1.1738056. PMID 22384458.
^ "New Drug Approvals 2012 - Pt. XIV - Mirabegron (Myrbetriq)". The ChEMBL-og.

v t e Urologicals, including antispasmodics (G04B)
Acidifiers	Ammonium chloride Calcium chloride
Urinary antispasmodics (primarily antimuscarinics)	Darifenacin Desfesoterodine Emepronium Fesoterodine Flavoxate Imidafenacin Meladrazine Mirabegron Oxybutynin Propiverine Solifenacin Terodiline Tolterodine Trospium chloride Vibegron
Other urologicals	Urea analogues: Acetohydroxamic acid Salicylhydroxamic acid Other: Collagen Dapoxetine Dimethyl sulfoxide Magnesium hydroxide Pentosan polysulfate Phenazopyridine Phenyl salicylate Succinimide Tiopronin

Drugs for functional gastrointestinal disorders (A03)

Drugs for
functional
bowel
disorders

Antimuscarinics

Tertiary amino group	Camylofin Dicycloverine Difemerine Dihexyverine Mebeverine Oxyphencyclimine Piperidolate Rociverine Trimebutine
Quaternary ammonium compounds	Benzilone Bevonium Diphemanil Fenpiverinium Glycopyrronium Hexocyclium Isopropamide Mepenzolate Methantheline Otilonium Oxyphenonium Penthienate Pipenzolate Poldine Prifinium Propantheline Tiemonium Timepidium Tridihexethyl